Navigation Links
ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010
Date:7/21/2010

EXTON, Pa., July 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2010 are expected to be released on Wednesday, July 28, 2010 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2010 second quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com .  An audio archive will be available at the same address until August 16, 2010.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for rout
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Senior supply ... and professional associations, addressed the challenges of “Reducing Cost, ... Device Industries” through strategic sourcing. Describing the partnership of ... the Supply Chain Management Institute ( SCMI) of ... on June 24 at the Kroc Institute of Peace ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... sunlight at a modest cost is a challenge with ... paper in a special energy issue of Optics ... a relatively new approach to solar cells: lacing them ... the article, this approach has the potential to greatly ...
... GREENBELT, Md. - Engineers at the University of Idaho ... in upcoming NASA missions that will study the Earth ... of a grant technical officer Pen-Shu Yeh, a senior ... the engineering team at the University of ...
... Md. - Engineers at the University of Idaho have ... upcoming NASA missions that will study the Earth and ... a grant technical officer Pen-Shu Yeh, a senior engineer ... engineering team at the University of Idaho,s ...
Cached Biology Technology:Enhancing solar cells with nanoparticles 2New one-of-a-kind technology will fly on 2 NASA missions 2New one-of-a-kind technology will fly on 2 NASA missions 3New one-of-a-kind technology will fly on two NASA missions 2New one-of-a-kind technology will fly on two NASA missions 3
(Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... varieties with higher yields and enhanced nutritional content, researchers ... with scientists at nine other institutions in an attempt ... endeavor, led by researchers at the U.K.-based Biotechnology and ... in the journal Nature . "This work ...
... release is available in Spanish . WASHINGTON, ... as part of an international team have completed a "shotgun sequencing" ... Nature reported today. The achievement is expected to increase ... wheat varieties with enhanced nutritional value. "By unlocking the ...
... code of one of the world,s most important crops. The ... genome, published today in Nature , is a major ... better able to cope with disease, drought and other stresses ... wheat genes, and insights into the links between them, lays ...
Cached Biology News:UC Davis researchers aid effort to sequence the complex wheat genome 2USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 2USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 3Major breakthrough in deciphering bread wheat's genetic code 2Major breakthrough in deciphering bread wheat's genetic code 3Major breakthrough in deciphering bread wheat's genetic code 4
... The VSOS-4 Orbital Shaker is designed to ... provide a uniform motion that is both mixing ... VSOS-4 Orbital Shaker provides a smooth, quiet, reproducible ... a wide range of laboratory applications such as ...
... Titer Kit is designed for determination of baculovirus ... days as in other methods. Classical determination of ... plaques, but the FastPlax Kit takes advantage of ... glycoprotein on the cell surface as early as ...
... state-of-the-art software for all your biopharmaceutical applications ... a single, scalable software package. The graphical ... the control of all Freedom instruments from ... 100 with one liquid handling arm up ...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
Biology Products: